The relevance of clinical stage in diagnosis of localized prostate cancer today

The staging systems used by clinicians and pathologists for assignment of the stage of prostate cancer were all developed more than 20 years ago, and have seen only relatively minor adjustments since the introduction of the PSA test. … READ MORE …

Is subclassification of stage T2 disease still relevant?

There are three pathological subclassifications of prostate cancer that is confined to the prostate: T2a disease (cancer confined to one half of either the left or right lobe or side of the prostate), T2b disease (cancer that is found throughout one lobe or side of the prostate) and T2c disease (cancer that is evident in both lobes or sides of the prostate). Historically, it has been considered that these stages of organ-confined prostate cancer are “different”with respect to risk for progression. However, new data suggests that this may not actually be the case. … READ MORE …

PSMA protein targeting agent and metastatic disease

According to a company press release, Molecular Insight Pharmaceuticals, Inc. presented clinical data earlier today on a development-stage, radiolabeled, small-molecule, molecular imaging pharmaceutical with potential in the diagnosis, staging, and perhaps even the treatment of advanced forms of prostate cancer. … READ MORE …

β-Arrestin 2: yet another possible marker

Another report from the Medical College of Georgia identifies a protein called β-arrestin 2 (or βarrestin2) as having lower levels in certain types of prostate cancer cells than in normal prostate cells, while expression of testosterone-stimulated androgen receptors is higher. … READ MORE …

The Thursday prostate cancer news: February 12, 2009

Four new reports today deal with:

  • Higher grade disease in men diagnosed with prostate cancer because of LUTS
  • The role of MR/MRI in prostate biopsy for carefully defined patients
  • Risk for understaging of prostate cancer
  • Sorenafib in treatment of patients with castration-resistant prostate cancer … READ MORE …

Thursday’s news update: November 20, 2008

We have separately addressed a report from Australia on the potential of PSA “signatures” as prognostic indicators of prostate cancer progression. In other news today: … READ MORE …

Weekend prostate cancer news update: Saturday, July 26

Articles summarized in this weekend news update include information about:

  • The value of endorectal MRI imaging in staging patients with respect to whether they have cancer confined to the prostate or extracapsular disease
  • Patterns of disease recurrence after salvage radical prostatectomy for patients with radiation-recurrent disease
  • The potential of PSA kinetics to improve prediction of likelihood for survival in men with hormone-refractory prostate cancer, and
  • The appropriateness of testosterone replacement therapy in men with hypogonadism after curative treatment for prostate cancer … MORE …